David P. Schenkein - Apr 3, 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Director
Signature
/s/ William Cook, as Attorney in Fact for David Schenkein
Stock symbol
AGIO
Transactions as of
Apr 3, 2023
Transactions value $
-$225,809
Form type
4
Date filed
4/5/2023, 04:03 PM
Previous filing
Mar 29, 2023
Next filing
Jun 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $148K +16.4K +13.88% $9.05 134K Apr 3, 2023 Direct F1
transaction AGIO Common stock Sale -$374K -16.4K -12.19% $22.85 118K Apr 3, 2023 Direct F2, F3
holding AGIO Common stock 271K Apr 3, 2023 See footnote F4
holding AGIO Common stock 79.1K Apr 3, 2023 See footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock option (right to buy) Options Exercise $0 -16.4K -100% $0.00* 0 Apr 3, 2023 Common stock 16.4K $9.05 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $22.49 to $23.42. The reporting person undertakes, upon request by the staff of the Securitiesand Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F5 Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F6 This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares.